A Phase II Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Jul 2016
At a glance
- Drugs Sorafenib (Primary) ; Erlotinib; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 23 Jan 2013 Planned End Date changed from 1 Sep 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 23 Dec 2011 Planned number of patients changed to 45.
- 20 May 2011 Planned end date changed from 1 Sep 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.